Can semaglutide delay kidney disease progression, and what do recent trial findings show in Europe?

Semaglutide and kidney disease explained: GLP-1 receptor agonist therapy, chronic kidney disease (CKD), albuminuria reduction, cardiovascular risk, and prescribing criteria.

In this episode, we review emerging trial data suggesting semaglutide may slow progression of chronic kidney disease in certain patients, and how doctors interpret these findings under EU medical guidance.

You’ll learn:

• What semaglutide is and how GLP-1 receptor agonists work

• The link between type 2 diabetes and chronic kidney disease

• How improved glycaemic control may reduce kidney strain

• Evidence on albuminuria reduction and renal outcomes

• The difference between slowing progression and rever ...